CN102048852A - Oral medicament for treating cerebral infarction and relieving limb spasm - Google Patents
Oral medicament for treating cerebral infarction and relieving limb spasm Download PDFInfo
- Publication number
- CN102048852A CN102048852A CN2010105946558A CN201010594655A CN102048852A CN 102048852 A CN102048852 A CN 102048852A CN 2010105946558 A CN2010105946558 A CN 2010105946558A CN 201010594655 A CN201010594655 A CN 201010594655A CN 102048852 A CN102048852 A CN 102048852A
- Authority
- CN
- China
- Prior art keywords
- parts
- present
- blood
- medicine
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to an oral medicament for treating cerebral infarction and relieving limb spasm, and the oral medicament is prepared from the following traditional Chinese medicine active ingredients in parts by weight: 12-40 parts of membranous milkvetch root, 12-40 parts of pachyrhizua angulatus, 10-25 parts of red paeony root, 10-25 parts of szechuan lovage rhizome, 10-20 parts of peach seed, 10-25 parts of suberect spatholobus stem, 10-25 parts of common clubmoss herb, 10-25 parts of glandularstalk st.paulswort herb, 6-20 parts of twotooth achyranthes root and 3-10 parts of earthworm. Efficacy tests prove that the medicament can obviously inhibit the in-vivo blood vessel thrombosis of an animal, reduce the weight of in-vivo arterial and venous thrombus, inhibit the thrombosis and alleviate the clinical symptoms caused by the thrombus; and the medicament further has certain effect of improving coagulation function of rats, and can reduce the platelet aggregation rate, prolong the coagulation time, the PT (prothrombin time) and the APTT (activated partial thromboplastin time), have an obvious effect of improving blood rheology indicators, and can be used for significantly reducing blood viscosity of a rat blood stasis model caused by polymer dextran, improving the blood circulation, and avoiding the potential risk of the thrombosis.
Description
Technical field
The invention belongs to the medicinal preparation technical field of the product that contains raw material or itself and not clear structure, be specifically related to derive from the material of plant.
Background technology
Apoplexy, claim apoplexy, cerebrovascular accident again, typically refer to the one group of acute illness that comprises cerebral hemorrhage, cerebral infarction, subarachnoid hemorrhage, concrete definition is meant Acute onset, the cerebrovascular property clinical events that occurs limitation or diffusivity brain function disappearance sign rapidly, be commonly encountered diseases, the frequently-occurring disease of middle-aged and elderly people, be one of three the highest big diseases of human now mortality rate, also be with fastest developing speed in the three big diseases, recover the slowest, the dead disease kind that at most, disables the heaviest, cause very big misery to the mankind, bring serious harm for family and society.And along with people's diet structure changes, rhythm of life is accelerated, the sickness rate of apoplexy rises year by year and the trend of rejuvenation is arranged.The whole world has 4,600,000 people to die from apoplexy every year, and die from apoplexy person domestic every year 1,600,000 crowd, and new cases 1,500,000 people are arranged, and total number of patients surpasses 5,000,000 people, serious harm human health and existence.And in all apoplexy, cerebral infarction accounts for 60%～80%, and as seen, the control of cerebral infarction has become the problem of world today's medical science and society's close attention.Cerebral infarction promptly is one of common clinical and frequently-occurring disease, and along with the development of modern diagnosis technology such as CT and MRI, the rate of examining out of cerebral infarction obviously improves in recent years.Primary disease also is obvious dependency with brain atrophy, vascular dementia, and patient's neurological functional deficit is increased the weight of gradually, directly influences old people's quality of life.
The medicine of at present commercially available treatment cerebral infarction specifically can be divided into two classes, one class is the old medicine of provincial standard of early stage listing, as HUATUO ZAIZAO WAN, ZHONGFENG HUICHUN WAN or the like, this series products without strict excessively at random, double blinding, contrast, multi-center clinical trial research, curative effect remains further to be proved conclusively, and indication is extensive, and curative effect is not concentrated; One class is the Chinese patent medicine ratified in recent years such as NAOAN JIAONANG, NAOXINTONG JIAONANG or the like, and this series products curative effect is comparatively definite, but is large and complete product, and curative effect is outstanding, and specific aim is not strong.
More than the indication of this two series products be apoplexy (cerebral infarction) convalescent period, but without exception be that these medicines are all at running through this pathology link of apoplexy " limb spasm " all the time.Occurring in the apoplexy (cerebral infarction) of limb spasm must occur, and no matter is acute stage, convalescent period, or sequela stage.Limb spasm usually is the principal element that the restriction apoplexy takes a turn for the better, the lifting of the recovery of paralytic's self care ability and patient's quality of life, depending on the recovery of limb spasm to a great extent, is the matter of utmost importance of being badly in need of solution in present paralytic's rehabilitation.
Summary of the invention
Technical problem to be solved by this invention is to overcome the shortcoming of said medicine, and the oral drugs of a kind of treatment cerebral infarction that has no side effect evident in efficacy and alleviation limb spasm are provided.
It is with the raw material of Chinese medicine of the following proportion by weight medicinal preparation for oral administration made of formulation method routinely to solve the problems of the technologies described above the technical scheme that adopted:
12～40 parts of the Radixs Astragali
12～40 parts of Pachyrhizua angulatus
10～25 parts of Radix Paeoniae Rubra
10～25 parts of Rhizoma Chuanxiongs
10～20 parts in Semen Persicae
10～25 parts of Caulis Spatholobis
10～25 parts of Herba Lycopodiis
10～25 parts of Herba Siegesbeckiaes
6～20 parts of Radix Achyranthis Bidentataes
3～10 parts of Pheretimas
Raw material of Chinese medicine best in quality part proportioning of preparation medicine of the present invention is:
27 parts of the Radixs Astragali
27 parts of Pachyrhizua angulatus
21 parts of Radix Paeoniae Rubra
18 parts of Rhizoma Chuanxiongs
15 parts in Semen Persicae
18 parts of Caulis Spatholobis
18 parts of Herba Lycopodiis
18 parts of Herba Siegesbeckiaes
12 parts of Radix Achyranthis Bidentataes
6 parts of Pheretimas
The medicinal preparation for oral administration that above-mentioned each component is made according to a conventional method is said tablet or granule or capsule or a syrup on the galenic pharmacy.
The preparation method of medicine capsule of the present invention is as follows:
Pachyrhizua angulatus medical material 90g beats powder, crosses 100 mesh sieves, and is standby; All the other Pachyrhizua angulatus medical materials and other nine flavors medical material decoct with water twice, add 10 times of water gagings for the first time and decoct 2 hours, add 8 times of water gagings for the second time and decoct 2 hours, filter, merging filtrate is concentrated into relative density 1.20 ± 0.05 (60 ℃), adds ethanol and makes and contain the alcohol amount and reach 50%, leaves standstill 24 hours, get supernatant, decompression recycling ethanol continues to be condensed into thick paste to there not being the alcohol flavor, adds Pachyrhizua angulatus medicated powder, mix homogeneously, oven dry is pulverized, cross 100 mesh sieves, granulate, oven dry, granulate, encapsulated, promptly.Every heavy 0.4g, every gram contains raw material of Chinese medicine 4.5g.
The preparation method of medicinal tablet of the present invention is as follows:
The used raw material of Chinese medicine of raw material of Chinese medicine that medicinal tablet of the present invention is used and quality proportioning and medicine capsule of the present invention is identical, the extraction process step of raw material of Chinese medicine is identical with the extraction process step of capsule preparation method thereof raw material of Chinese medicine of the present invention, and used adjuvant and other processing step are undertaken by the conventional preparation technology of tablet.Every heavy 0.4g, every gram contains crude drug 4.5g.
The preparation technology of medicinal granule of the present invention is as follows:
The used raw material of Chinese medicine of raw material of Chinese medicine that medicinal granule of the present invention is used and quality proportioning and medicine capsule of the present invention is identical, the extraction process step of raw material of Chinese medicine is identical with the extraction process step of capsule preparation method thereof raw material of Chinese medicine of the present invention, and used adjuvant and other processing step are undertaken by the conventional preparation technology of granule.Every bag heavy 5g, every gram contains raw material of Chinese medicine 1.44g.
The preparation technology of medicine oral liquid of the present invention is as follows:
Raw material of Chinese medicine that medicine oral liquid of the present invention is used and weight proportion and medicine capsule of the present invention are identical, the extraction process step of raw material of Chinese medicine is identical with the extraction process step of capsule preparation method thereof raw material of Chinese medicine of the present invention, and used adjuvant and other processing step carry out according to the conventional preparation technology of oral liquid.Every bottle of 10mL, every milliliter contains raw material of Chinese medicine 0.72g.
Show that through the test of pesticide effectiveness medicine of the present invention can obviously suppress the formation of vascular thrombosis in the animal body, reduce the weight of the artery and vein thrombosis that forms in the body, suppress the formation of thrombosis, can alleviate the clinical symptoms that causes because of thrombosis; The rat coagulation function there is certain influence, can reduce platelet aggregation rate, obviously prolong clotting time, PT and APTT, hemorheology index is also improved significantly, can significantly reduce the blood viscosity of rat blood stasis model due to the high molecular dextran, improve blood circulation, avoided thrombotic potential risk effectively; In influence test to large and small Mus cerebral ischemic model, medicine of the present invention can significantly reduce the oxygen supply of blocking-up brain blood supply, and cause the degree of injury of cerebral tissue hypoxic-ischemic, the rat model neuroethology is improved significantly, reduce the infarct size and the cerebral edema of cerebral tissue, breathe the time after can prolonging the mice broken end, promote keeping of normal brain activity function; Medicine of the present invention can effectively improve the neuroethology symptom of rats with cerebral ischemia model, reduces the damage of brain and nervous tissue.Prove that medicine of the present invention has the function of the brain tissue impairment that protection causes because of hypoxic-ischemic, have the scope that reduces cerebral infarction, alleviate the cerebral tissue edema, blood viscosity lowering prolongs clotting time, suppresses the pharmacological actions such as formation of thrombosis; Have benefiting QI for activating blood circulation aspect Chinese medicine, the effect of disperse blood stasis and dredge collateral is applicable to the hemiplegia due to the stroke in convalescent stage (cerebral infarction), facial hemiparalysis, body stolidity partially, limb spasm, dysphonia etc. belong to syndrome of blood stasis due to qi deficiency person.
The specific embodiment
The present invention is described in more detail below in conjunction with embodiment, but the invention is not restricted to these embodiment.
Embodiment 1
With 1000 of production medicine capsule products of the present invention is that the used raw material of Chinese medicine of example and adjuvant and proportioning thereof are:
Radix Astragali 270g
Pachyrhizua angulatus 270g
Radix Paeoniae Rubra 210g
Rhizoma Chuanxiong 180g
Semen Persicae 150g
Caulis Spatholobi 180g
Herba Lycopodii 180g
Herba Siegesbeckiae 180g
Radix Achyranthis Bidentatae 120g
Pheretima 60g
Dextrin adds to 400g
Its preparation method is as follows:
Get ten flavor medical materials such as the Radix Astragali, Pachyrhizua angulatus medical material 90g beats powder, crosses 100 mesh sieves, and is standby; All the other Pachyrhizua angulatus medical materials and other nine flavors medical material decoct with water twice, add 10 times of water gagings for the first time and decoct 2 hours, add 8 times of water gagings for the second time and decoct 2 hours, filter, merging filtrate is concentrated into relative density 1.20 ± 0.05 (60 ℃ of surveys), adds ethanol and makes and contain the alcohol amount and reach 50%, leaves standstill 24 hours, get supernatant, decompression recycling ethanol continues to be condensed into thick paste to there not being the alcohol flavor, add Pachyrhizua angulatus medicated powder, mix homogeneously, oven dry, pulverize, cross 100 mesh sieves, granulate, oven dry, granulate is adorned 1000 capsules.Every heavy 0.4g, every gram contains raw material of Chinese medicine 4.5g.
With 1000 of production medicinal tablet products of the present invention is that the used raw material of Chinese medicine of example and adjuvant and proportioning thereof are:
Raw material that the present embodiment tablet is used and quality proportioning thereof and capsule are identical, and used adjuvant dextrin such as uses to replace at the starch of quality, and its preparation method is undertaken by the preparation method of tablet of the present invention.Every heavy 0.4g, every gram contains raw material of Chinese medicine 4.5g.
With production granule product of the present invention 1000g is that the used raw material of Chinese medicine of example and adjuvant and quality proportioning thereof are:
Radix Astragali 216g
Pachyrhizua angulatus 216g
Radix Paeoniae Rubra 168g
Rhizoma Chuanxiong 144g
Semen Persicae 120g
Caulis Spatholobi 144g
Herba Lycopodii 144g
Herba Siegesbeckiae 144g
Radix Achyranthis Bidentatae 96g
Pheretima 48g
Sucrose 400g
Dextrin adds to 1000g.
Its preparation technology is undertaken by the preparation technology of granule of the present invention.Every bag heavy 5g, every gram contains raw material of Chinese medicine 1.44g.
With production oral liquid product of the present invention 1000mL is that the used raw material of Chinese medicine of example and adjuvant and quality proportioning thereof are:
Radix Astragali 108g
Pachyrhizua angulatus 108g
Radix Paeoniae Rubra 84g
Rhizoma Chuanxiong 72g
Semen Persicae 60g
Caulis Spatholobi 72g
Herba Lycopodii 72g
Herba Siegesbeckiae 72g
Radix Achyranthis Bidentatae 48g
Pheretima 24g
Sucrose 400g
Distilled water adds to 1000mL.
Its preparation technology is undertaken by the preparation technology of oral liquid of the present invention.Every bottle of 10mL, every milliliter contains raw material of Chinese medicine 0.72g.
In the proportioning of present embodiment, the mass parts of each component of raw material of Chinese medicine is:
18 parts of 21 parts of Rhizoma Chuanxiongs of 27 parts of Radix Paeoniae Rubra of 27 parts of Pachyrhizua angulatus of the Radix Astragali
18 parts of 18 parts of Herba Lycopodiis of 15 portions of Caulis Spatholobis of Semen Persicae, 18 Fen Herba Siegesbeckiaes
6 parts of 12 parts of Pheretimas of Radix Achyranthis Bidentatae
Embodiment 2
With 1000 of production medicine capsule products of the present invention is that the used raw material of Chinese medicine of example and adjuvant and proportioning thereof are:
Radix Astragali 231g
Pachyrhizua angulatus 231g
Radix Paeoniae Rubra 194g
Rhizoma Chuanxiong 194g
Semen Persicae 194g
Caulis Spatholobi 194g
Herba Lycopodii 194g
Herba Siegesbeckiae 194g
Radix Achyranthis Bidentatae 116g
Pheretima 58g
Dextrin adds to 400g
Its preparation technology is identical with the preparation technology of embodiment 1 capsule.Every heavy 0.4g, every gram contains raw material of Chinese medicine 4.5g.
With 1000 of production medicinal tablet products of the present invention is that the used raw material of Chinese medicine of example and adjuvant and proportioning thereof are as follows:
Raw material that the present embodiment tablet is used and quality proportioning thereof and capsule are identical, and used adjuvant dextrin such as uses to replace at the starch of quality, and its preparation method is undertaken by the preparation method of tablet of the present invention.Every heavy 0.4g, every gram contains raw material of Chinese medicine 4.5g.
With production granule product of the present invention 1000g is that the used raw material of Chinese medicine of example and adjuvant and quality proportioning thereof are:
Radix Astragali 186g
Pachyrhizua angulatus 186g
Radix Paeoniae Rubra 155g
Rhizoma Chuanxiong 155g
Semen Persicae 155g
Caulis Spatholobi 155g
Herba Lycopodii 155g
Herba Siegesbeckiae 155g
Radix Achyranthis Bidentatae 92g
Pheretima 46g
Sucrose 400g
Dextrin adds to 1000g.
Its preparation technology is undertaken by the preparation technology of granule of the present invention.Every bag heavy 5g, every gram contains raw material of Chinese medicine 1.44g.
With production oral liquid product of the present invention 1000mL is that the used raw material of Chinese medicine of example and adjuvant and quality proportioning thereof are:
Radix Astragali 94g
Pachyrhizua angulatus 94g
Radix Paeoniae Rubra 77g
Rhizoma Chuanxiong 77g
Semen Persicae 77g
Caulis Spatholobi 77g
Herba Lycopodii 77g
Herba Siegesbeckiae 77g
Radix Achyranthis Bidentatae 47g
Pheretima 23g
Sucrose 400g
Distilled water adds to 1000mL.
Its preparation technology is undertaken by the preparation technology of oral liquid of the present invention.Every bottle of 10mL, every milliliter contains raw material of Chinese medicine 0.72g.
In the proportioning of present embodiment, the mass parts of each component of raw material of Chinese medicine is:
10 parts of 10 parts of Rhizoma Chuanxiongs of 12 parts of Radix Paeoniae Rubra of 12 parts of Pachyrhizua angulatus of the Radix Astragali
10 parts of 10 parts of Herba Lycopodiis of 10 portions of Caulis Spatholobis of Semen Persicae, 10 Fen Herba Siegesbeckiaes
3 parts of 6 parts of Pheretimas of Radix Achyranthis Bidentatae
Embodiment 3
With 1000 of production medicine capsule products of the present invention is that the used raw material of Chinese medicine of example and adjuvant and proportioning thereof are:
Radix Astragali 282g
Pachyrhizua angulatus 282g
Radix Paeoniae Rubra 176g
Rhizoma Chuanxiong 176g
Semen Persicae 141g
Caulis Spatholobi 177g
Herba Lycopodii 177g
Herba Siegesbeckiae 177g
Radix Achyranthis Bidentatae 141g
Pheretima 71g
Dextrin adds to 400g
Its preparation technology is identical with the preparation technology of embodiment 1 capsule.Every heavy 0.4g, every gram contains raw material of Chinese medicine 4.5g.
With 1000 of production medicinal tablet products of the present invention is that the used raw material of Chinese medicine of example and adjuvant and proportioning thereof are:
Raw material that the present embodiment tablet is used and quality proportioning thereof and capsule are identical, and used adjuvant dextrin such as uses to replace at the starch of quality, and its preparation method is undertaken by the preparation method of tablet of the present invention.Every heavy 0.4g, every gram contains raw material of Chinese medicine 4.5g.
With production granule product of the present invention 1000g is that the used raw material of Chinese medicine of example and adjuvant and quality proportioning thereof are:
Radix Astragali 226g
Pachyrhizua angulatus 226g
Radix Paeoniae Rubra 141g
Rhizoma Chuanxiong 141g
Semen Persicae 113g
Caulis Spatholobi 141g
Herba Lycopodii 141g
Herba Siegesbeckiae 141g
Radix Achyranthis Bidentatae 113g
Pheretima 57g
Sucrose 400g
Dextrin adds to 1000g.
Its preparation technology is undertaken by the preparation technology of granule of the present invention.Every bag heavy 5g, every gram contains raw material of Chinese medicine 1.44g.
With production oral liquid product of the present invention 1000mL is that the used raw material of Chinese medicine of example and adjuvant and quality proportioning thereof are:
Radix Astragali 113g
Pachyrhizua angulatus 113g
Radix Paeoniae Rubra 71g
Rhizoma Chuanxiong 71g
Semen Persicae 56g
Caulis Spatholobi 71g
Herba Lycopodii 71g
Herba Siegesbeckiae 71g
Radix Achyranthis Bidentatae 56g
Pheretima 27g
Sucrose 400g
Distilled water adds to 1000mL.
Its preparation technology is undertaken by the preparation technology of oral liquid of the present invention.Every bottle of 10mL, every milliliter contains raw material of Chinese medicine 0.72g.
In the proportioning of present embodiment, the mass parts of each component of raw material of Chinese medicine is:
25 parts of 25 parts of Rhizoma Chuanxiongs of 40 parts of Radix Paeoniae Rubra of 40 parts of Pachyrhizua angulatus of the Radix Astragali
25 parts of 25 parts of Herba Lycopodiis of 20 portions of Caulis Spatholobis of Semen Persicae, 25 Fen Herba Siegesbeckiaes
10 parts of 20 parts of Pheretimas of Radix Achyranthis Bidentatae
In order to verify the therapeutic effect of medicine of the present invention to cerebral infarction, the applicant adopts the medicine capsule of the present invention (name is called logical brain RONGSHUAN JIAONANG during test) of the embodiment of the invention 1 proportioning preparation to entrust preclinical medicine institute of Chengdu University of Traditional Chinese Medicine to carry out pharmacodynamics test, and various test situation are as follows:
Test objective: observe the pharmacodynamic action of medicine of the present invention to the empty syndrome of blood stasis of centering pathogenic wind, with and the effect characteristics, for clinical research provides foundation.
Experimental apparatus: multi-path physiology function instrument, model: RM6280C is produced by Chengdu Instruement Factory; Electronic analytical balance, model are AB204-N, are produced by Mettler-Toledo Instrument (Shanghai) Co., Ltd.; Blood cell automatic analyzer, model are MEK-6318K, and Japanese photoelectricity company sells; Coagulo meter: model is PK-B, is sold by the Pei Kang of Zhongshan city Medical Treatment Electron Co., Ltd; Tabletop refrigerated centrifuge, model are TGL-16G, are sold by Anting Scientific Instrument Factory, Shanghai; Blood viscosity analyser, model are YDA-IV, and Hong Run development in science and technology company limited in Beijing is produced; Cellanalyzer, model are MEK-5216, and Shanghai Photoelectricity Medical electron Instrument Co., Ltd. produces;
Experimental drug: medicine capsule of the present invention; Lot number: 081201; Character: brown to brown granular.
Reagent: sodium carboxymethyl cellulose (CMC-Na), lot number: 20081120, produce by the Long Huagongshijichang of Chengdu section; Pentobarbital sodium, lot number: 060222, producer: Beijing chemical reagents corporation; Phosphate buffer (PBS), edta buffer liquid, EDTA-buffered formaldehyde liquid; Chlorination-2,3, the 5-triphenyltetrazolium chloride, lot number: 20070723, produce by the East China Normal University chemical plant; 10% high molecular dextran, lot number: 301622 production units: Amersham.Biosciences; 0.5% heparin-saline solution, authentication code are the accurate word H12020505 of traditional Chinese medicines, and the Tianjin Biochemical Pharmaceutical Factory produces:
Stability: ambient stable; Dissolubility: water soluble ' specification: 0.4g/ grain (containing 1.8g crude drug/grain).
Compound method: be that 0.5% sodium carboxymethyl cellulose (CMC-Na) suspends invention medicine capsule content and is mixed with desired concn with mass fraction.
Positive control medicine: XUESHUANXINMAINING capsule, lot number: 081102; Specification: 0.5g/ grain; Clinical consumption: 4/time, 3 times on the 1st, produce by Jilin Huakang Pharmaceutical Co., Ltd.
Function cures mainly: benefiting QI for activating blood circulation, the pain relieving of having one's ideas straightened out.Be used for apoplexy, the thoracic obstruction due to the blood stasis due to qi deficiency, disease opinion is had a dizzy spell, hemiplegia, pained, shortness of breath and palpitation uncomfortable in chest; Cerebral infarction convalescent period, angina pectoris are seen above-mentioned patient.
Rat dosage is provided with and foundation: capsule of the present invention, the clinical plan dosage of people is 21.6g crude drug/people. day, by body weight 60kg calculating for each person, promptly be equivalent to 0.36g crude drug/kg. people. day.Press the body surface area conversion, be equivalent to rat dosage 2.1g crude drug/kg.bw.With this dosage is dosage in the rat oral gavage, it 1/2 is a low dosage, and its 2 times is high dose, and irritating and being made into concentration respectively with 0.5%CMC-Na solution before the stomach is 0.42g crude drug/ml, 0.21g crude drug/ml, 0.105g crude drug/ml, press the 1ml/100g gastric infusion, 1 time on the one.
The XUESHUANXINMAINING capsule: specification 0.5g/ grain, 4/time of the clinical usages of people, 3 times/day, every day, total amount was 6g/ people. day, by body weight 60kg calculating for each person, promptly be equivalent to 0.1g/kg.Press the body surface area conversion, the dosage that is equivalent to rat is 0.58g/kg.bw.With this dosage is rat positive controls dosage, and irritating stomach preceding is the 0.058g/ml suspension with mass fraction for 0.5%CMC-Na solution is made into concentration, presses the 1ml/100g gastric infusion, one day 1 time (referring to table 1).
Table 1 invention medicine capsule is to the animal grouping and the dosage regimen of artery thrombosis influence test in the rat body
Rat route of administration and administration volume: gastric infusion, 1ml/100g.
Animal animal: SD rat; Grade: one-level; Quantity: 50; Weight: 250-300g; Sex: male and female half and half; Supplying unit: Chengdu University of Traditional Chinese Medicine's Experimental Animal Center; The animal quality certification number: SCXK (river) 2008-12
1, medicine capsule of the present invention is to the influence of artery thrombosis in the rat body
Experimental technique: getting body weight is totally 50 of the SD rats (male and female half and half) of 250～300g, be divided into 5 groups at random by sex, body weight, be respectively solvent matched group, positive controls and the basic, normal, high dosage group of medicament capsule agent capsules of the present invention, 10 every group, male and female half and half.According to dosage regimen, it is 0.5% CMC-Na that the solvent matched group is irritated the isopyknic mass fraction of stomach, and all the other each groups are irritated stomaches and given corresponding be subjected to test product CMC-Na suspension, successive administration 25 days, 1 time/day.
Successive administration 25 days, 30min after the administration in the 25th day, rats by intraperitoneal injection 0.3% pentobarbital sodium 30mg/kg anesthesia, cause the rat carotid artery thrombus model, current settings 4mA, stimulation time 7min, skin suture steams again and raises afterwards, should note the sterile working in the operation.Continuous again gastric infusion 5d, the last administration is after 1 hour, and rat is anaesthetized once more, and the cervical region median incision takes out the common carotid artery that comprises thrombosis, blots blood and moisture on filter paper, the precision weighing thrombus weight.
Utilization spss11.0 statistical software carries out statistical analysis, and each group is carried out statistical analysis with the method for solvent matched group utilization sided t check.
Result of the test sees Table 2.
Table 2 medicine capsule of the present invention to the influence of artery thrombosis in the rat body (
N=10)
Annotate: compare with the solvent matched group, " * " represents P＜0.05; " * * " represents P＜0.01.
As shown in Table 2, behind the rat oral gavage positive control drug XUESHUANXINMAINING capsule, the wet weight of thrombus that forms in the carotid artery is starkly lower than solvent matched group (P＜0.05), and the illustrative experiment system sets up.The logical middle and high dosage group of brain thrombolytic wet weight of thrombus is starkly lower than solvent matched group (P＜0.05 or 0.01), illustrates that logical brain RONGSHUAN JIAONANG has certain resisting in the thrombotic pharmacodynamics function of body.
2, medicine capsule of the present invention is to the thrombotic influence of rat body angular vein
Experimental technique: get 50 of the SD rats of body weight 250～300g, be divided into 5 groups at random, be respectively the basic, normal, high dosage group of solvent matched group, positive controls and medicine capsule of the present invention by body weight, 10 every group, male and female half and half.It is 0.5% CMC-Na that the solvent matched group is irritated the isopyknic mass fraction of stomach, and all the other each groups are irritated stomaches and given the corresponding test product aqueous solution that is subjected to, successive administration January, 1 time/day (referring to table 1).
After the last administration 1 hour, rat was cut the about 3cm of skin with 10% chloral hydrate 0.3ml/100g intraperitoneal injection of anesthesia in ventrimeson, separates postcava, in the left renal vein below with thick line ligation postcava, the stitching stomach wall.After 4 hours, reopen the abdominal cavity, folder stopped pipe chamber, 2cm place exhausts this section tube chamber inner blood below ligation, cuts tube chamber open, and removal of thromboses is placed on the filter paper, blots blood, takes by weighing wet weight of thrombus.With the thrombus weight is evaluation index, measures the influence of each administration group to venous thrombosis.
Utilization spss11.0 statistical software carries out statistical analysis, and each group is carried out statistical analysis with the method for solvent matched group utilization sided t check.
Experimental result sees Table 3.
Table 3 medicine capsule of the present invention to the thrombotic influence of rat body angular vein (
N=10)
Annotate: compare with the solvent matched group, " * " represents P＜0.05; " * * " represents P＜0.01.
As shown in Table 3, behind the rat oral gavage positive control drug XUESHUANXINMAINING capsule, the wet weight of thrombus that forms in the postcava is starkly lower than solvent matched group (P＜0.05), and the illustrative experiment system sets up.The basic, normal, high dosage group of medicine capsule of the present invention wet weight of thrombus is starkly lower than solvent matched group (P＜0.05 or 0.01), illustrates that logical brain RONGSHUAN JIAONANG has certain resisting in the thrombotic pharmacodynamics function of body.
3, medicine capsule of the present invention is to the influence of rat platelet aggregation and coagulation function
Phosphate buffer preparation: KCl 2g, KH
2PO
42g, NaCl 80g, Na
2HPO
48.8g adding distil water is to 1000ml, adjust pH to 7.4; The preparation of edta buffer liquid: 0.077mol/L EDTA 3ml adds PBS 5ml, again adding distil water 12ml; The preparation of EDTA-buffered formaldehyde liquid: 0.077mol/L EDTA 3ml adds 4% formalin 5ml, adds PBS 2ml, distilled water 10ml again, adjust pH to 7.4.
Experimental technique: get 50 of body weight 250～300g SD rats, be divided into 5 groups at random, be respectively the basic, normal, high dosage group of solvent matched group, positive controls and medicine capsule of the present invention by the sex body weight, 10 every group, male and female half and half.It is 0.5% CMC-Na that the solvent matched group is irritated the isopyknic mass fraction of stomach, and all the other each groups are irritated stomaches and given corresponding test product CMC-Na suspension, the successive administration 30 days (referring to table 1) of being subjected to.
30min after the last administration, each Mus ip 3mg/ml pentobarbital sodium solution 1ml/100g anesthesia is that the capillary glass tube insertion Mus angular vein clump of 1mm is got blood with internal diameter, reaches 5cm to the capillary blood post.Every fracture one section in capillary tube of 30s, check to have or not clotting strands to occur, calculate capillary tube and take a blood sample to and the blood clotting silk time occurs, be clotting time.Face upward fixedly rat of position then, open abdomen and expose ventral aorta and postcava, earlier, discard the about 0.1ml of blood of injector head, the blood of remainder is injected the 5ml plastic centrifuge tube respectively with the 5ml syringe postcava blood sampling 0.5ml that 2ml edta buffer liquid and EDTA-buffered formaldehyde liquid are housed respectively, mixing, room temperature is placed 15min, with the centrifugal 10min of 500r/min, gets upper plasma, measure the PLT number, calculate the PLT aggregation rate.
PLT number * 100% in PLT aggregation rate=(PLT number-EDTA-formaldehyde delays PLT number in the liquid in the edta buffer liquid)/edta buffer liquid.
In addition with 3.2% sodium citrate and EDTAK
2Vacuum test tube from the ventral aorta blood sampling, is measured PLT and TT, PT, APTT respectively immediately.
Utilization spss11.0 statistical software carries out statistical analysis, and each group is carried out statistical analysis with the method for solvent matched group utilization sided t check.Experimental result sees Table 4,5.
Table 4 medicine capsule of the present invention to the influence of rat clotting time (
N=10)
Annotate: compare with the solvent matched group, " * " represents P＜0.05; " * * " represents P＜0.01.
Table 5 medicine capsule of the present invention to the influence of rat platelet aggregation and coagulation function (
N=10)
Annotate: compare with the solvent matched group, " * " represents P＜0.05; " * * " represents P＜0.01.
From table 4 and table 5 result as can be known, positive controls XUESHUANXINMAINING capsule has certain influence to the rat coagulation function, can prolong clotting time and PT time, reduces platelet aggregation rate; Dosage group and solvent group relatively can prolong the blood clotting time (P＜0.05) in the medicine capsule of the present invention; Middle and high dosage group of medicine capsule of the present invention and solvent group are relatively, can reduce platelet aggregation rate, prolong the PT time, low, high dose group and the comparison of solvent group can prolong the APTT time (P＜0.05 or 0.01), illustrate that this is subjected to test product certain pharmacological action to be arranged to the rat coagulation function.
4, medicine capsule of the present invention is to the protective effect of rat ischemia brain injury
Experimental technique: get body weight 250～300g SD rat, be divided into 6 groups at random, be respectively the basic, normal, high dosage group of Sham-operated control group, model control group, positive controls and medicine capsule of the present invention by the sex body weight, 20 every group, male and female half and half.The CMC-Na of stomach isopyknic 0.5% is irritated in the contrast of sham operated rats and model, and all the other each groups are irritated stomaches and given corresponding test product CMC-Na suspension, successive administration January (referring to table 1) of being subjected to.
Prepare the nylon embolus by longa EZ method.
12h fasting before the art is behind last administration 0.5h, with 10% chloral hydrate anesthesia (300mg/kg).Adopt improvement Zea longa method, rat is lain on the back on operating-table, partial insulation (about about 37 ℃), neck medisection is separated right carotid (CCA), external carotid artery (ECA), internal carotid artery (ICA) is pricked right side ECA and arteria pterygopalatina with No. 0 toe-in, and, internal carotid artery crotch outer near neck slowly inserts above-mentioned ready nylon embolus line by common carotid artery along internal carotid artery, the line insertion depth is about 18-20mm, then otch is carried out routine and sews up.After sham operated rats is only separated common carotid artery, the inside and outside tremulous pulse of neck and arteria pterygopalatina, skin suture, the postoperative animal is noted insulation.After 24 hours, observe the survival rats behavior and change, carry out behavior scoring.
Standards of grading: by 5 minutes of Zea Longa systems branch standard of appraising one's merits: 0 minute, normal, impassivity damage symptom; 1 minute, can not full extension offside fore paw; 2 minutes, turn-take laterally; 3 minutes, topple over to offside; 4 minutes, can not spontaneously walk loss of consciousness.
Broken end is got the Mus brain fast.A part (8 every group) is divided another name left and right sides brain hemisphere weight in wet base, puts in 160 ℃ of baking boxs to claim dry weight behind the 24h, calculates brain water content as follows: brain water content (%)=(weight in wet base-dry weight)/weight in wet base * 100%; A part (8 every group) is removed olfactory bulb, cerebellum and low brain stem ,-20 ℃ of freezing 10min, and coronal section is cut into the 5-6 sheet, places 2%TTC solution at once, hatches 30min for 37 ℃.Infarct presents white, and non-infarct presents redness.After the TTC dyeing, normal saline flushing 2 times of brain sheet separate infarct and normal cerebral tissue, and infarct and normal cerebral tissue are carried out weighing.The percentage ratio that accounts for big brain weight with blocking tissue's weight is as the infarct volume index.
Utilization spss11.0 statistical software carries out statistical analysis, and each group is carried out statistical analysis with the method for model control group utilization sided t check.Experimental result table 6-8.
Table 6 medicine capsule of the present invention is learned scoring to rats with cerebral ischemia model nervous symptoms
Annotate: compare with model control group, " * " represents P＜0.05; " * * " represents P＜0.01.Down together.
The logical brain RONGSHUAN JIAONANG of table 7 is to the influence of rats with cerebral ischemia model brain water content
The logical brain RONGSHUAN JIAONANG of table 8 is to the influence of rats with cerebral ischemia model cerebral infarction rate
From table 6-8 result as can be known, sham operated rats detects every index and model control group has significant difference (P＜0.01), and the model establishment is described.Positive controls XUESHUANXINMAINING capsule can effectively improve its nervous symptoms scoring, cerebral edema and cerebral infarction scope to the rats with cerebral ischemia model, with model control group significant difference (P＜0.05 or 0.01) is arranged relatively, meet its pharmacotoxicological effect characteristics, simultaneously prove that also experimental system is credible, can be used for the analysis of test sample drug action.The scoring of the middle and high dosage group of medicine capsule of the present invention nervous symptoms, cerebral edema and cerebral infarction scope and model control group relatively have significant difference (P＜0.05 or 0.01); Low dose group has certain pharmacology's trend improving on the cerebral ischemia index, but test data system there was no significant difference (P＞0.05).In sum, medicine capsule of the present invention can be protected the hypoxia on rat brain tissue injury, improves the ability of cerebral tissue anoxia enduring.
5, medicine capsule of the present invention is to the ischemic brain injury protective effect
Medicine capsule of the present invention: the clinical plan dosage of people is 21.6g crude drug/people. day, by body weight 60kg calculating for each person, promptly be equivalent to 0.36g crude drug/kg. people. day.Press the body surface area conversion, be equivalent to mice dosage 4.2g crude drug/kg.With this dosage is dosage in the mouse stomach, it 1/2 is a low dosage, and its 2 times is high dose, and irritating and being made into concentration respectively with 0.5%CMC-Na solution before the stomach is 0.42g crude drug/ml, 0.21g crude drug/ml, 0.105g crude drug/ml, press the 0.2ml/10g gastric infusion, 1 time/day.
The XUESHUANXINMAINING capsule: specification 0.5g/ grain, 4/time of the clinical usages of people, 3 times/day, every day, total amount was 6g/ people. day, by body weight 60kg calculating for each person, promptly be equivalent to 0.1g/kg.Press the body surface area conversion, the dosage that is equivalent to mice is 1.17g/kg.With this dosage is mice positive controls dosage, and being made into concentration with 0.5%CMC-Na solution before the filling stomach is the 0.059g/ml suspension, presses the 0.2ml/10g gastric infusion, 1 time/d (referring to table 9).
Table 9 medicine capsule of the present invention is to the test dosage regimen of mice ischemic brain injury protective effect
Gastric infusion, 0.2ml/10g.
Laboratory animal: Kunming mouse; One-level, 50,18-22g, male and female half and half, Chengdu University of Traditional Chinese Medicine's Experimental Animal Center, the animal quality certification number: SCXK (river) 2008-11.
Experimental technique: get 50 of mices, be divided into 5 groups at random, be respectively the basic, normal, high dosage group of solvent matched group, positive controls and medicine capsule of the present invention, 10 every group, male and female half and half.The solvent matched group is irritated the CMC-Na of stomach isopyknic 0.5%, and all the other each groups are irritated stomaches and given corresponding test product CMC-Na suspension, the successive administration 30 days (referring to table 9) of being subjected to.
Behind last administration 30min, under the not anesthesia situation, to break end fast with shears lower edge after Mice Auricle, the record mice broken end time, promptly mice breathed the time to the dwell time of breathing.
Utilization spss11.0 statistical software carries out statistical analysis, and each group is carried out statistical analysis with the method for model control group utilization sided t check.
Experimental result sees Table 10.
Table 10 medicine capsule of the present invention to decapitated mice breathe the persistent period influence (
N=10)
Annotate: compare with the solvent matched group, " * " represents P＜0.05; " * * " represents P＜0.01.
From table 10 interpretation of result, the XUESHUANXINMAINING capsule has obvious prolongation effect to the mice broken end time of breathing, and compares P＜0.05 with the solvent matched group, illustrates that this pilot system is reliable, can be used for the analysis of test sample drug action.Basic, normal, high dosage group of medicine capsule of the present invention and solvent matched group relatively have significant difference (P＜0.05 or 0.01), show that medicine capsule of the present invention has the certain protection anoxia to brain tissue injury, improve the ability that mouse brain is organized anoxia enduring.
6, medicine capsule of the present invention influences the blood stasis hemorheology of rat
Experimental technique: get 60 of body weight 200～250g SD rats, be divided into 6 groups at random, be respectively the basic, normal, high dosage group of solvent matched group, model control group, positive controls and medicine capsule of the present invention by body weight, 10 every group, male and female half and half.Solvent contrast and model control group are irritated the CMC-Na of stomach isopyknic 0.5%, and all the other each groups are irritated stomaches and given the corresponding test product CMC-Na suspension that is subjected to, successive administration January, 1 time/day (referring to table 1).
1h after the last administration, rat tail vein is injected 10% high molecular dextran (0.5ml/100g), behind the 15min, abdominal aortic blood 6-7ml, get 1ml whole blood EDTA anticoagulant and measure packed cell volume, get 0.8ml whole blood anticoagulant heparin with suction pipe and measure whole blood viscosity, all the other blood centrifugal 10 minutes with 2000rpm are got 0.8ml blood plasma and are surveyed plasma viscosity and packed cell volume (HCT).
Utilization spss11.0 statistical software carries out statistical analysis, and each group is carried out statistical analysis with the method for model control group utilization sided t check.Experimental result sees Table 11.
Table 11 medicine capsule of the present invention influences blood stasis rat model hemorheology
Annotate: compare with model control group, " * " represents P＜0.05; " * * " represents P＜0.01.
As known from Table 11, after rat tail vein is injected 10% high molecular dextran modeling, each index of hemorheology of rat and solvent matched group more all have significant difference (P＜0.05 or 0.01), positive controls rat whole blood and blood plasma shear rate and model control group have significant difference (P＜0.05 or 0.01), meet its pharmacotoxicological effect characteristics.Cut in the middle and high dosage group of the medicine capsule of the present invention whole blood, Gao Qie and blood plasma shear rate and model control group relatively have significant difference (P＜0.05 or 0.01), medicine capsule high dose group whole blood low shear rate of the present invention and model control group relatively have significant difference (P＜0.01), illustrate that medicine capsule of the present invention can significantly reduce blood viscosity, improves blood circulation.
7, conclusion (of pressure testing)
The pharmacodynamic experiment result of study shows that medicine capsule of the present invention can obviously suppress the formation of vascular thrombosis in the animal body, reduces the weight of the artery and vein thrombosis that forms in the body, suppresses the formation of thrombosis, thereby can alleviate the clinical symptoms that causes because of thrombosis; Simultaneously, this capsule has certain influence to the rat coagulation function, can reduce platelet aggregation rate, obviously prolong clotting time, PT and APTT, hemorheology index is also improved significantly, can significantly reduce the blood viscosity of rat blood stasis model due to the high molecular dextran, improve blood circulation, thereby avoided thrombotic potential risk effectively, embodied the blood circulation promoting and blood stasis dispelling that medicine capsule of the present invention had, the function of collateral dredging; In influence test to large and small Mus cerebral ischemic model, medicine capsule of the present invention can significantly reduce because of adopting the oxygen supply of artificial method blocking-up brain blood supply, and cause the degree of injury of cerebral tissue hypoxic-ischemic, scoring improves significantly to the rat model neuroethology, reduce the infarct size and the cerebral edema situation of cerebral tissue, simultaneously, can prolong and breathe the time after mice breaks end, promote keeping of normal brain activity function.Chinese medicine is thought QI can promote blood circulation, and blood can be driven gas.Deficiency of vital energy person often accompanies the blood walking retardation in children to stagnate, and blood stasis or disease such as hemorrhage can occur.Gas can not promoting the circulation of blood, then difficult up the moistening of blood supported clear key, brain loses and to moisten foster, stagnation of blood stasis and see hemiplegia, facial hemiparalysis, inclined to one side body stolidity, limb spasm, dysphonia etc., medicine capsule of the present invention can effectively improve the neuroethology symptom of rats with cerebral ischemia model, reduces the damage of brain and nervous tissue, has embodied the function of the activating qi and collateral in the Chinese medicine.
Prove that medicine capsule of the present invention has the function of the brain tissue impairment that protection causes because of hypoxic-ischemic, have the scope that reduces cerebral infarction, alleviate the cerebral tissue edema, blood viscosity lowering prolongs clotting time, suppresses the pharmacological actions such as formation of thrombosis; Have benefiting QI for activating blood circulation aspect Chinese medicine, the effect of disperse blood stasis and dredge collateral is applicable to the hemiplegia due to the stroke in convalescent stage (cerebral infarction), facial hemiparalysis, body stolidity partially, limb spasm, dysphonia etc. belong to syndrome of blood stasis due to qi deficiency person.
Function of the present invention cures mainly: benefiting QI for activating blood circulation, disperse blood stasis and dredge collateral.Cure mainly the hemiplegia due to the stroke in convalescent stage (cerebral infarction), facial hemiparalysis, body stolidity partially, limb spasm, dysphoniaes etc. belong to the syndrome of blood stasis due to qi deficiency person.
The specification of medicine of the present invention: every heavy 0.4g of medicine capsule of the present invention, every gram contains raw material of Chinese medicine 4.5g; Every heavy 0.4g of medicinal tablet of the present invention, every gram contains crude drug 4.5g; Every bag heavy 5g of medicinal granule of the present invention, every gram contains raw material of Chinese medicine 1.44g; Every bottle of 10mL of medicine oral liquid of the present invention, every milliliter contains raw material of Chinese medicine 0.72g.
The usage of medicine of the present invention and consumption: oral medicine capsule of the present invention, one time 4,3 times on the one; Oral medicinal tablet of the present invention, one time 4,3 times on the one; Oral medicinal granule of the present invention, boiled water is taken after mixing it with water, one time one bag, 3 times on the one; Oral medicine oral liquid of the present invention, one time 1 bottle, 3 times on the one.
Banking system: normal temperature drying is preserved.
Claims (2)
1. oral drugs for the treatment of cerebral infarction and alleviating limb spasm is characterized in that it is by the raw material of Chinese medicine of the following proportion by weight medicinal preparation for oral administration of formulation method preparation routinely:
12～40 parts of the Radixs Astragali
12～40 parts of Pachyrhizua angulatus
10～25 parts of Radix Paeoniae Rubra
10～25 parts of Rhizoma Chuanxiongs
10～20 parts in Semen Persicae
10～25 parts of Caulis Spatholobis
10～25 parts of Herba Lycopodiis
10～25 parts of Herba Siegesbeckiaes
6～20 parts of Radix Achyranthis Bidentataes
3～10 parts of Pheretimas.
2. according to the oral drugs of described treatment cerebral infarction of claim 1 and alleviation limb spasm, it is characterized in that the proportion by weight of raw material of Chinese medicine is:
27 parts of the Radixs Astragali
27 parts of Pachyrhizua angulatus
21 parts of Radix Paeoniae Rubra
18 parts of Rhizoma Chuanxiongs
15 parts in Semen Persicae
18 parts of Caulis Spatholobis
18 parts of Herba Lycopodiis
18 parts of Herba Siegesbeckiaes
12 parts of Radix Achyranthis Bidentataes
6 parts of Pheretimas.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010105946558A CN102048852B (en) | 2010-12-17 | 2010-12-17 | Oral medicament for treating cerebral infarction and relieving limb spasm |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010105946558A CN102048852B (en) | 2010-12-17 | 2010-12-17 | Oral medicament for treating cerebral infarction and relieving limb spasm |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102048852A true CN102048852A (en) | 2011-05-11 |
| CN102048852B CN102048852B (en) | 2012-05-23 |
Family
ID=43953869
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010105946558A Expired - Fee Related CN102048852B (en) | 2010-12-17 | 2010-12-17 | Oral medicament for treating cerebral infarction and relieving limb spasm |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102048852B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103083559A (en) * | 2013-01-10 | 2013-05-08 | 山东凤凰制药股份有限公司 | Novel preparation method and application of traditional Chinese medicine composition for treating cerebral infarction during acute stage and earlier restoration stage |
| CN116327824A (en) * | 2023-03-09 | 2023-06-27 | 上海中医药大学附属岳阳中西医结合医院 | Traditional Chinese medicine composition with detoxifying and vein relaxing functions and preparation method and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1187996A (en) * | 1997-01-13 | 1998-07-22 | 李国华 | Drug for curing cerebral infarction |
| CN1569095A (en) * | 2003-07-24 | 2005-01-26 | 陈淑清 | Medicine for treating cerebral infarction |
-
2010
- 2010-12-17 CN CN2010105946558A patent/CN102048852B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1187996A (en) * | 1997-01-13 | 1998-07-22 | 李国华 | Drug for curing cerebral infarction |
| CN1569095A (en) * | 2003-07-24 | 2005-01-26 | 陈淑清 | Medicine for treating cerebral infarction |
Non-Patent Citations (2)
| Title |
|---|
| 《陕西中医》 19920430 张学安，刘翠瑛 中西医结合治疗脑梗塞178例临床分析 156-157 1-2 第13卷, 第4期 * |
| 《陕西中医》 19920430 张学安，刘翠瑛 中西医结合治疗脑梗塞178例临床分析 156-157 1-2 第13卷, 第4期 2 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103083559A (en) * | 2013-01-10 | 2013-05-08 | 山东凤凰制药股份有限公司 | Novel preparation method and application of traditional Chinese medicine composition for treating cerebral infarction during acute stage and earlier restoration stage |
| CN116327824A (en) * | 2023-03-09 | 2023-06-27 | 上海中医药大学附属岳阳中西医结合医院 | Traditional Chinese medicine composition with detoxifying and vein relaxing functions and preparation method and application thereof |
| CN116327824B (en) * | 2023-03-09 | 2024-04-02 | 上海中医药大学附属岳阳中西医结合医院 | Traditional Chinese medicine composition with detoxifying and vein relaxing functions and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102048852B (en) | 2012-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101982193B (en) | Traditional Chinese medicine composition for treating pulmonary tuberculosis, preparation method and application thereof | |
| CN101085000A (en) | Compound red sage root freezing-dried powder injection containing salvianolic acid B and its preparation method | |
| CN102397462A (en) | Oral liquid used for resisting aging, preparation method thereof, and quality controlling method thereof | |
| CN102048852B (en) | Oral medicament for treating cerebral infarction and relieving limb spasm | |
| CN1692914B (en) | Application of timosaponin B II for preparing medicine or products for treating and preventing stroke | |
| CN101537159B (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
| CN102526676B (en) | Traditional Chinese medicine for treating chronic heart failure, preparation method and administration mode | |
| CN101623437B (en) | Pulse-activating preparation for injection and preparation method thereof | |
| CN103405501B (en) | Preparation method of three-component blood-activating and stasis-dissolving capsules | |
| CN100509010C (en) | Chinese medicinal preparation for treating cardiovascular and cerebrovascular diseases and preparation method thereof | |
| CN102488838A (en) | Traditional Chinese medicine composition used for treating viral myocarditis | |
| CN102293985B (en) | Traditional Chinese medicine composition used for treating coronary heart disease and preparation method thereof | |
| CN101062027B (en) | Taurine and medical combination for treating cardiovascular and cerebrovascular diseases | |
| CN102961517A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular disease | |
| CN102068520A (en) | Chinese medicinal composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof | |
| CN101947299B (en) | Medicinal composition for treating coronary heart disease | |
| CN106361829B (en) | Traditional Chinese medicine composition and preparation for treating ischemic stroke and preparation method thereof | |
| CN100415241C (en) | Medicinal composition for treating cardio-cerebrovascular diseases | |
| CN116898897B (en) | Primordial qi-tonifying, hypoxia-resisting and chronic fatigue-conditioning primordial qi-preserving soup recipe and preparation method thereof | |
| CN102370735B (en) | Application of traditional Chinese medicinal composition in preparation of medicament for treating polycythemia | |
| CN101628022A (en) | Safflower dripping pill and preparation method thereof | |
| CN105687499A (en) | Betaxolol containing pharmaceutical composition for treating hypertension and preparation method thereof | |
| CN101549050B (en) | Traditional Chinese medicine composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof | |
| CN100488513C (en) | Medicine for treating cerebrovascular and cardiovascular diseases and preparation process thereof | |
| CN100443093C (en) | AIDS treating medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120523 Termination date: 20181217 |